Leukoencephalopathy after prophylactic radiation for leukaemia in ataxia telangiectasia

J A Eyre1, D Gardner-Medwin, G P Summerfield

  • 1Department of Child Health, Medical School, University of Newcastle upon Tyne.

Insights

Children with ataxia telangiectasia (AT) face a higher risk of acute lymphoblastic leukemia (ALL) and are sensitive to cancer treatments. This case highlights a child with undiagnosed AT who developed leukoencephalopathy after ALL treatment.

Area of Science:

  • Pediatric Oncology
  • Neuro-oncology
  • Genetics

Background:

  • Ataxia telangiectasia (AT) is a rare genetic disorder with increased cancer risk, particularly acute lymphoblastic leukemia (ALL).
  • Patients with AT exhibit heightened sensitivity to DNA-damaging agents like chemotherapy and radiation therapy.
  • Central nervous system (CNS) prophylaxis is a standard treatment for ALL to prevent or treat leukemia spread to the brain.

Observation:

  • A 5.5-year-old boy presented with acute lymphoblastic leukemia (ALL) while having an undiagnosed condition of ataxia telangiectasia (AT).
  • The patient received conventional chemotherapy and irradiation as part of his ALL treatment protocol.
  • Following treatment, the child developed leukoencephalopathy, a serious neurological condition affecting the brain's white matter.

Findings:

  • This case illustrates the complex interplay between AT, ALL, and treatment-related toxicities.
  • The development of chemoradiation-induced leukoencephalopathy underscores the heightened sensitivity of AT patients to standard ALL therapies.
  • Undiagnosed AT can complicate the management of pediatric leukemia, leading to severe adverse events.

Implications:

  • Early diagnosis of AT in children presenting with leukemia is crucial for tailoring treatment plans.
  • Treatment protocols for pediatric leukemia in patients with AT may require modification to mitigate risks of severe neurotoxicity.
  • This case emphasizes the need for increased awareness and vigilance among clinicians regarding AT complications in leukemia patients.